Rapid and Effective Neuronal Conversion of Human Glioblastoma In Vitro and In Vivo Using Potent Small Molecules

Abstract

Exploring effective, prompt and universally applicable approaches for inducing the differentiation of glioblastoma (GBM) into terminally differentiated cells, such as astrocytes or neurons that cease cell division, is pivotal for the success of GBM differentiation therapy. In this study, a neuronal-specific promoter–reporter system was employed to screen small molecules that promote neural differentiation. The cocktail YFSS, consisting of Y27632, Forskolin, SB431542 and SP600125, which selectively targets the ROCK, cAMP, TGF-β and JNK signalling pathways, respectively, was found to effectively trigger differentiation in human GBM cells. This process yielded neuron-like cells within 7 days, inhibited GBM cell proliferation and reduced malignancy traits, such as stemness, migratory and invasive capabilities. Transcriptome sequencing revealed the pathways altered by YFSS, shedding light on its dual role in halting cell proliferation and initiating neuronal differentiation. A notable increase in CEND1 expression, a key molecule in cell cycle and neuronal differentiation regulation, was observed during differentiation. However, CEND1 alone could not replicate YFSS's high conversion efficiency and its depletion reduced the differentiation and restored proliferation of the GBM cells. In vivo, prolonged and localised YFSS application significantly curtailed tumour growth and extended survival in patient-derived xenograft mice models. In summary, our findings reveal that the small-molecule cocktail YFSS is an effective means for inducing neuronal differentiation in GBM cells, representing a novel and promising pathway for the advancement of GBM treatment.

Keywords

CEND1 / differentiation therapy / glioblastoma / neuron-like cells / small molecules

References

[1] D. N. Louis, A. Perry, G. Reifenberger, et al., “The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A Summary,” Acta Neuropathologica 131, no. 6 (2016): 803-820.

[2] E. G. Van Meir, C. G. Hadjipanayis, A. D. Norden, H. K. Shu, P. Y. Wen, and J. J. Olson, “Exciting New Advances in Neuro-Oncology: The Avenue to a Cure for Malignant Glioma,” CA: A Cancer Journal for Clinicians 60, no. 3 (2010): 166-193.

[3] Z. Su, T. Zang, M. L. Liu, L. L. Wang, W. Niu, and C. L. Zhang, “Reprogramming the Fate of Human Glioma Cells to Impede Brain Tumor Development,” Cell Death & Disease 5, no. 10 (2014): e1463.

[4] J. Liu, X. Wang, A. T. Chen, et al., “ZNF117 Regulates Glioblastoma Stem Cell Differentiation Towards Oligodendroglial Lineage,” Nature Communications 13, no. 1 (2022): 2196.

[5] M. Yan and Q. Liu, “Differentiation Therapy: A Promising Strategy for Cancer Treatment,” Chinese Journal of Cancer 35 (2016): 3.

[6] H. El Hajj, Z. Dassouki, C. Berthier, et al., “Retinoic Acid and Arsenic Trioxide Trigger Degradation of Mutated NPM1, Resulting in Apoptosis of AML Cells,” Blood 125, no. 22 (2015): 3447-3454.

[7] S. Masciarelli, E. Capuano, T. Ottone, et al., “Retinoic Acid and Arsenic Trioxide Sensitize Acute Promyelocytic Leukemia Cells to ER Stress,” Leukemia 32, no. 2 (2018): 285-294.

[8] H. Caren, S. Beck, and S. M. Pollard, “Differentiation Therapy for Glioblastoma—Too Many Obstacles?,” Molecular & Cellular Oncology 3, no. 2 (2016): e1124174.

[9] P. Hou, Y. Li, X. Zhang, et al., “Pluripotent Stem Cells Induced From Mouse Somatic Cells by Small-Molecule Compounds,” Science 341, no. 6146 (2013): 651-654.

[10] D. Biswas and P. Jiang, “Chemically Induced Reprogramming of Somatic Cells to Pluripotent Stem Cells and Neural Cells,” International Journal of Molecular Sciences 17, no. 2 (2016): 226.

[11] N. Cao, Y. Huang, J. Zheng, et al., “Conversion of Human Fibroblasts Into Functional Cardiomyocytes by Small Molecules,” Science 352, no. 6290 (2016): 1216-1220.

[12] J. Oh, Y. Kim, L. Che, et al., “Regulation of cAMP and GSK3 Signaling Pathways Contributes to the Neuronal Conversion of Glioma,” PLoS One 12, no. 11 (2017): e0178881.

[13] C. Lee, M. Robinson, and S. M. Willerth, “Direct Reprogramming of Glioblastoma Cells Into Neurons Using Small Molecules,” ACS Chemical Neuroscience 9, no. 12 (2018): 3175-3185.

[14] X. Liu, C. Guo, T. Leng, et al., “Differential Regulation of H3K9/H3K14 Acetylation by Small Molecules Drives Neuron-Fate-Induction of Glioma Cell,” Cell Death & Disease 14, no. 2 (2023): 142.

[15] J. Yuan, F. Zhang, D. Hallahan, et al., “Reprogramming Glioblastoma Multiforme Cells Into Neurons by Protein Kinase Inhibitors,” Journal of Experimental & Clinical Cancer Research 37, no. 1 (2018): 181.

[16] A. Tzortzopoulos, D. Thomaidou, M. Gaitanou, R. Matsas, and E. Skoulakis, “Expression of Mammalian BM88/CEND1 in Drosophila Affects Nervous System Development by Interfering With Precursor Cell Formation,” Neuroscience Bulletin 35, no. 6 (2019): 979-995.

[17] P. K. Politis, G. Makri, D. Thomaidou, M. Geissen, H. Rohrer, and R. Matsas, “BM88/CEND1 Coordinates Cell Cycle Exit and Differentiation of Neuronal Precursors,” Proceedings of the National Academy of Sciences of the United States of America 104, no. 45 (2007): 17861-17866.

[18] L. Katsimpardi, M. Gaitanou, C. E. Malnou, et al., “BM88/Cend1 Expression Levels Are Critical for Proliferation and Differentiation of Subventricular Zone-Derived Neural Precursor Cells,” Stem Cells 26, no. 7 (2008): 1796-1807.

[19] K. Aravantinou-Fatorou, F. Ortega, D. Chroni-Tzartou, et al., “CEND1 and NEUROGENIN2 Reprogram Mouse Astrocytes and Embryonic Fibroblasts to Induced Neural Precursors and Differentiated Neurons,” Stem Cell Reports 5, no. 3 (2015): 405-418.

[20] K. Aravantinou-Fatorou, S. Vejdani, and D. Thomaidou, “Cend1 and Neurog2 Efficiently Reprogram Human Cortical Astrocytes to Neural Precursor Cells and Induced-Neurons,” International Journal of Developmental Biology 66, no. 1-2-3 (2022): 199-209.

[21] Z. Houjun and B. Peng, “Down-Regulation of CEND1 Expression Contributes to the Progression and Temozolomide Resistance of Glioma,” Cell Journal 25, no. 4 (2023): 264-272.

[22] L. A. Hasselbach, S. M. Irtenkauf, N. W. Lemke, et al., “Optimization of High Grade Glioma Cell Culture From Surgical Specimens for Use in Clinically Relevant Animal Models and 3D Immunochemistry,” Journal of Visualized Experiments 83 (2014): e51088.

[23] Y. Hu, F. Zhang, W. Zhong, et al., “Transplantation of Neural Scaffolds Consisting of Dermal Fibroblast-Reprogrammed Neurons and 3D Silk Fibrous Materials Promotes the Repair of Spinal Cord Injury,” Journal of Materials Chemistry B 7, no. 47 (2019): 7525-7539.

[24] Y. Hu, J. Lu, X. Xu, J. Lyu, and H. Zhang, “Regulation of Focal Adhesion Turnover in SDF-1alpha-Stimulated Migration of Mesenchymal Stem Cells in Neural Differentiation,” Scientific Reports 7, no. 1 (2017): 10013.

[25] J. K. Sa, N. Chang, H. W. Lee, et al., “Transcriptional Regulatory Networks of Tumor-Associated Macrophages That Drive Malignancy in Mesenchymal Glioblastoma,” Genome Biology 21, no. 1 (2020): 216.

[26] F. O. Enane, Y. Saunthararajah, and M. Korc, “Differentiation Therapy and the Mechanisms That Terminate Cancer Cell Proliferation Without Harming Normal Cells,” Cell Death & Disease 9, no. 9 (2018): 912.

[27] H. de The, “Differentiation Therapy Revisited,” Nature Reviews. Cancer 18, no. 2 (2018): 117-127.

[28] A. Jogi, M. Vaapil, M. Johansson, and S. Pahlman, “Cancer Cell Differentiation Heterogeneity and Aggressive Behavior in Solid Tumors,” Upsala Journal of Medical Sciences 117, no. 2 (2012): 217-224.

[29] D. Ishay-Ronen, M. Diepenbruck, R. K. R. Kalathur, et al., “Gain Fat-Lose Metastasis: Converting Invasive Breast Cancer Cells Into Adipocytes Inhibits Cancer Metastasis,” Cancer Cell 35, no. 1 (2019): 17-32 e16.

[30] D. Floryk, S. L. Tollaksen, C. S. Giometti, and E. Huberman, “Differentiation of Human Prostate Cancer PC-3 Cells Induced by Inhibitors of Inosine 5′-Monophosphate Dehydrogenase,” Cancer Research 64, no. 24 (2004): 9049-9056.

[31] J. Mai, J. Gu, Y. Liu, et al., “Negative Regulation of miR-1275 by H3K27me3 Is Critical for Glial Induction of Glioblastoma Cells,” Molecular Oncology 13, no. 7 (2019): 1589-1604.

[32] X. Wang, Z. Pei, A. Hossain, Y. Bai, and G. Chen, “Transcription Factor-Based Gene Therapy to Treat Glioblastoma Through Direct Neuronal Conversion,” Cancer Biology & Medicine 18, no. 3 (2021): 860-874.

[33] J. Lee, M. J. Son, K. Woolard, et al., “Epigenetic-Mediated Dysfunction of the Bone Morphogenetic Protein Pathway Inhibits Differentiation of Glioblastoma-Initiating Cells,” Cancer Cell 13, no. 1 (2008): 69-80.

[34] H. Sabelstrom, R. Petri, K. Shchors, et al., “Driving Neuronal Differentiation Through Reversal of an ERK1/2-miR-124-SOX9 Axis Abrogates Glioblastoma Aggressiveness,” Cell Reports 28, no. 8 (2019): 2064-2079 e2011.

[35] K. Matsuda, A. Sato, M. Okada, et al., “Targeting JNK for Therapeutic Depletion of Stem-Like Glioblastoma Cells,” Scientific Reports 2 (2012): 516.

[36] J. L. Birch, B. J. Coull, L. C. Spender, et al., “Multifaceted Transforming Growth Factor-Beta (TGFbeta) Signalling in Glioblastoma,” Cellular Signalling 72 (2020): 109638.

[37] A. Bruna, R. S. Darken, F. Rojo, et al., “High TGFbeta-Smad Activity Confers Poor Prognosis in Glioma Patients and Promotes Cell Proliferation Depending on the Methylation of the PDGF-B Gene,” Cancer Cell 11, no. 2 (2007): 147-160.

[38] E. A. Meyers and J. A. Kessler, “TGF-Beta Family Signaling in Neural and Neuronal Differentiation, Development, and Function,” Cold Spring Harbor Perspectives in Biology 9, no. 8 (2017): a022244.

[39] N. Golestaneh and B. Mishra, “TGF-beta, neuronal stem cells and glioblastoma,” Oncogene 24, no. 37 (2005): 5722-5730.

[40] J. V. Joseph, V. Balasubramaniyan, A. Walenkamp, and F. A. Kruyt, “TGF-Beta as a Therapeutic Target in High Grade Gliomas - Promises and Challenges,” Biochemical Pharmacology 85, no. 4 (2013): 478-485.

[41] L. Cheng, L. Gao, W. Guan, et al., “Direct Conversion of Astrocytes Into Neuronal Cells by Drug Cocktail,” Cell Research 25, no. 11 (2015): 1269-1272.

[42] W. Hu, B. Qiu, W. Guan, et al., “Direct Conversion of Normal and Alzheimer's Disease Human Fibroblasts Into Neuronal Cells by Small Molecules,” Cell Stem Cell 17, no. 2 (2015): 204-212.

[43] N. Georgopoulou, C. Hurel, P. K. Politis, M. Gaitanou, R. Matsas, and D. Thomaidou, “BM88 Is a Dual Function Molecule Inducing Cell Cycle Exit and Neuronal Differentiation of Neuroblastoma Cells via Cyclin D1 Down-Regulation and Retinoblastoma Protein Hypophosphorylation,” Journal of Biological Chemistry 281, no. 44 (2006): 33606-33620.

[44] E. P. Erkan, T. Strobel, G. Lewandrowski, et al., “Depletion of Minichromosome Maintenance Protein 7 Inhibits Glioblastoma Multiforme Tumor Growth In Vivo,” Oncogene 33, no. 39 (2014): 4778-4785.

[45] C. Lee, A. Fotovati, J. Triscott, et al., “Polo-Like Kinase 1 Inhibition Kills Glioblastoma Multiforme Brain Tumor Cells in Part Through Loss of SOX2 and Delays Tumor Progression in Mice,” Stem Cells 30, no. 6 (2012): 1064-1075.

[46] K. Tsioras, F. Papastefanaki, P. K. Politis, R. Matsas, and M. Gaitanou, “Functional Interactions Between BM88/Cend1, Ran-Binding Protein M and Dyrk1B Kinase Affect Cyclin D1 Levels and Cell Cycle Progression/Exit in Mouse Neuroblastoma Cells,” PLoS One 8, no. 11 (2013): e82172.

[47] N. Magne, V. Rousseau, K. Duarte, et al., “PAK3 Is a Key Signature Gene of the Glioma Proneural Subtype and Affects Its Proliferation, Differentiation and Growth,” Cellular Oncology 44, no. 6 (2021): 1257-1271.

[48] H. Bulstrode, E. Johnstone, M. A. Marques-Torrejon, et al., “Elevated FOXG1 and SOX2 in Glioblastoma Enforces Neural Stem Cell Identity Through Transcriptional Control of Cell Cycle and Epigenetic Regulators,” Genes & Development 31, no. 8 (2017): 757-773.

[49] A. Kosti, P. R. de Araujo, W. Q. Li, et al., “The RNA-Binding Protein SERBP1 Functions as a Novel Oncogenic Factor in Glioblastoma by Bridging Cancer Metabolism and Epigenetic Regulation,” Genome Biology 21, no. 1 (2020): 195.

[50] R. Lane, C. Cilibrasi, J. Chen, et al., “PDGF-R Inhibition Induces Glioblastoma Cell Differentiation via DUSP1/p38(MAPK) Signalling,” Oncogene 41, no. 19 (2022): 2749-2763.

RIGHTS & PERMISSIONS

2025 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.